Page 8 - Oncology_11_2021
P. 8
the dendritic cells began stimulating Accord Oncology Portfolio
SPECIALITY
regression. Instead, using single-
7 cell RNA sequencing technology, T cells to attack tumor cells.
they identified a previously unknown
cell line with a type of colon activation state of DC2 cells, a Targeted therapy
carcinoma, which forms tumors that different type of dendritic cell, that
grow larger after being implanted was driving T cell activation in the Some types of interferon have been
in the body. The researchers found regressing tumors. used to help treat cancer, but it can
that in the progressing tumors, the have widespread side effects when
T cell response quickly became The MIT team found that instead given systemically. The findings
exhausted, while in the regressing of ingesting cellular debris, these from this study suggest that it could
tumors, T cells remained functional. dendritic cells swipe proteins called be beneficial to deliver interferon
MHC complexes from tumor cells in a very targeted way to tumor
The researchers then analyzed and display them on their own cells, or to use a drug that would
the dendritic cell populations that surfaces. When T cells encounter provoke tumor cells to produce type
were present in each of these these dendritic cells masquerading I interferon, Spranger says.
tumors. One of the main functions as tumor cells, the T cells become
of dendritic cells is to take up strongly activated and begin killing The researchers now plan to
debris from dying cells, such as the tumor cells. investigate just how much type I
cancer cells or cells infected with interferon is needed to generate a
a pathogen, and then present the This specialized population of strong T cell response. Most tumor
protein fragments to T cells, alerting dendritic cells appears to be cells produce a small amount of
them to the infection or tumor. activated by type one interferon, type I interferon but not enough to
a signaling molecule that cells activate the dendritic cell population
The best-known type of dendritic usually produce in response to viral that invigorates T cells. On the other
cells required for antitumor infection. The researchers found a hand, too much interferon can be
immunity are DC1 cells, which small population of these dendritic toxic to cells.
interact with T cells that are able cells in colon and melanoma tumors
to eliminate cancer cells. However, that progress, but they were not “Our immune system is hardwired
the researchers found that DC1 properly activated. However, if they to respond to nuanced differences
cells were not needed for tumor treated those tumors with interferon, in type I interferon very dramatically,
and that is something that is
intriguing from an immunological
perspective,” Spranger says.
The research was funded by the
Koch Institute Support (core) Grant THE MOST EXPERIENCED BORTEZOMIB
GENERIC IN SOUTH AFRICA 1
from the National Cancer Institute, a
National Institutes of Health Pre-
Doctoral Training Grant, a David H.
Koch Graduate Fellowship, and the
Pew-Steward Fellowship.
Story Source:
Materials provided by AZACITIDINE 1 mg & 3,5 mg
Massachusetts Institute of
Technology. Original written by
Anne Trafton. Note: Content may be
edited for style and length.
Journal Reference:
1. Ellen Duong, Tim B. Fessenden,
Emi Lutz, Teresa Dinter, Leon Yim,
Sarah Blatt, Arjun Bhutkar, Karl
Dane Wittrup, Stefani Spranger.
Type I interferon activates MHC QUALITY ONCOLOGY PRODUCTS MADE ACCESSIBLE AND AFFORDABLE TO MORE SOUTH AFRICANS
class I-dressed CD11b conventional
dendritic cells to promote protective Reference: 1. Oncodata March 2021.
anti-tumor CD8 T cell immunity. S4 VALTIB 1 mg (powder for solution for injection). Each vial contains 1,0 mg bortezomib. Reg. No.: 52/26/1027. S4 VALTIB 3,5 mg (powder for solution for injection). Each vial contains 3,5 mg bortezomib.
Immunity, 2021; DOI: 10.1016/j. The reconstituted solution for intravenous injection contains 1,0 mg/ml bortezomib. Reg. No.: 49/26/0891. S4 PEMETREXED ACCORD 100 mg (lyophilised powder for solution for infusion). Each 4 ml
vial contains pemetrexed disodium hemipentahydrate equivalent to 100 mg pemetrexed. Reg. No. 52/26/1002. S4 PEMETREXED ACCORD 500 (lyophilised powder for solution for infusion). Each 20 ml
immuni.2021.10.020 vial contains pemetrexed disodium hemipentahydrate equivalent to 500 mg pemetrexed. Reg. No. 49/26/0888. S4 GRASTIVA 300 mg (pre-filled syringe). Each 0,5 ml pre-filled syringe contains 300 μg
filgrastim. Reg. No: 48/30.4/1114. S4 GRASTIVA 480 mg (pre-filled syringe). Each 0,5 ml pre-filled syringe contains 480 μg filgrastim. Reg. No: 48/30.4/1115. S4 INTAZA 100 mg (lyophilised powder for
suspension for injection). Each vial contains 100 mg azacitidine. Reg. No.: 51/26/0453.452. For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority.
ACCORD HEALTHCARE SA. Building 2, Tuscany Office Park, 6 Coombe Place, Rivonia, Johannesburg, South Africa. Tel: +27 11 234 5701/2/3. www.accord-healthcare.co.za. ACC/015/SEP21/AD
8
2021/09/20 10:23
QUO645 Accord-NEJM-A4Advert v3 FA.indd 1
QUO645 Accord-NEJM-A4Advert v3 FA.indd 1 2021/09/20 10:23
